Alex Brill, CEO of Matrix Global Advisors and author of a Generic Pharmaceuticals Association-commissioned study that claims FDA's proposal to require generic drug companies unilaterally update safety information on their products' labels would lead to $4 billion in annual increases for payers due to a 5.4 percent average increase on the cost of generic drugs, and that some manufacturers could exit the industry, flatly rejects trial lawyers' critique of his study. Brill has penned a point-by-point rebuttal, broken into what...